Knowde Enhanced TDS
Identification & Functionality
- Ingredient Name
- Ingredient Origin
- Pharma & Nutraceuticals Functions
- Ingredients
- Epimedium brevicornum Maxim Extract, Dioscorea Nipponica Makino Extract, Salvia Miltiorrhiza Bunge Extract
Features & Benefits
- Benefit Claims (Health)
- Labeling Claims
- Food Ingredients Features
- Product Background
JointAlive® is a patented formulation of standardized extracts of Discorea nipponica Makino rhizome , Epimedium brevicornum Maxim leaves and Salvia miltiorrhiza Bunge root and rhizome to help maintain a healthy joint and mobility function notified New Dietary Ingredient (NDI), NDIN 1172.
- Product Highlights
- Clinically proven efficacy
- Established mechanism of action
- Small dose per day
- Fast-acting and long-lasting, many users can feel it in 2 days
- 100% herbal formula
- Its development was based on 2,000-year Traditional Chinese Medicine history.
- No-GMO, Allergen-free, KOSHER, HALAL
- NDI notification
- Patented to cover manufacturing, composition and application
- Toxicity study confirms the safety
- Health Benefits
- Relieves Joint Pain as Quick as 7 Days
- Reduces Joint Inflammation and Swelling
- Improves Joint Flexibility and Mobility
Applications & Uses
- Applications
- Food & Nutrition Applications
- Dosage and Forms
Amount Per Serving %Daily Value JointAlive® (D. nipponica Makino rhizome extract,
Epimedium leaf extract, Chinese Salvia root and rhizome extract)300 mg Application
JointAlive® can be formulated in both capsule and tablet form alone or with glucosamine, MSM, chondroitin sulfate and other ingredients to maintain long-term joint health.
Dosage and Target Population
Target Population Dosage and Administration Exercise enthusiasts with joint discomforts As a dietary supplement, take 300 mg daily for 3 months, preferably with meals. Then stop taking it for a month. Do these 2 processes in turn. Middle-aged and elderly with osteoarthritis caused by joint degeneration Phase 1: As a dietary supplement, take 1200 mg and 600 mg daily for a month and 2 months respectively, preferablywith meals. Then stop taking it for a month.
Phase 2: Take 600 mg daily for 3 months, preferably with meals. Then stop taking it for a month. Take turns in these 2 processes.
People with joint problems caused by disease As a dietary supplement, take 1200 mg daily for 3 months, preferably with meals. Then stop taking it for a month. Take turns in these 2 processes.
Regulatory & Compliance
Technical Details & Test Data
- Human Clinical Study
- A 180-day, multi-center, open-label human clinical study was conducted to prove the efficacy and safety of JointAlive®.
- The subjects aged between 60 and 75 years old with arthritis were enrolled.
- The results showed JointAlive® can relieve joint discomfort as quick as 2 days and with long lasting effects.
- The feedback suggested that JointAlive® could also improve their waist, shoulder, neck health.
- Hematology, urine, blood pressure and electrocardiogram results showed no significant differences before and after the treatment, indicating the safety of JointAlive®.
- A single center, randomized, double-blind, placebo controlled parallel study was conducted to study the safety and efficacy of JointAlive® in relieving joint pain/swelling/stiffness and increasing joint flexibility in men and women with mild to moderate knee osteoarthritis.
- 72 healthy elderly men and women (36 participants in each group) were selected with mild to moderate knee osteoarthritis.
ClinicalTrials.gov Identifier: NCT04395547.
- JointAlive® boosts joint health by reducing inflammatory cytokines
- Mass spectrometry-based proteomics were used along with label-free quantitative proteomics to identify the effectiveness of JointAlive® against a rat OA model along with mechanism analysis.
- Proteomic and bioinformatic analysis revealed that the protective mechanism of JointAlive® was found to be linked to the depression of the humoral immune response in the MAPK & PI3K/AKT pathway to inhibit the expression of inflammatory factors and increase leukocyte mediated immunity.
- Promotes joint health through regulating humoral immune system
- Reduces the expression of pro-inflammatory genes and proteins
- Inhibits the expression of inflammatory factors, such as IL-6, IL-1 ß , TNF- α, MMPs, PEG2, COX-2 etc
- Improves the circulation of inflammatory cytokines
JointAlive® can promote joint health through reducing the serum concentration of
inflammatory factors
JointAlive® effectively increased the joint pain threshold of arthritic rats and reduced pain sensitivity
